港股异动 | 心通医疗-B(02160)再涨超5% ANCHORMAN®左心耳封堵器系统及其导引系统获得CE标志批准

智通财经2025-02-27

智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨5.38%，报0.98港元，成交额828.86万港元。消息面上，心通医疗-B(02160)发布公告，AnchorMan®左心耳封堵器系统及其导引系统已获得CE标志(表明欧洲经济区内所售产品符合健康、安全及环保标准的认证标志)批准。AnchorMan®左心耳封堵器系统和AnchorMan®左心耳导引系统均已获得中国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2514016810?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-27 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514016810","market":"sh","top_or_hot":-1,"title":"港股异动 | 心通医疗-B(02160)再涨超5% ANCHORMAN®左心耳封堵器系统及其导引系统获得CE标志批准","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨5.38%，报0.98港元，成交额828.86万港元。消息面上，心通医疗-B(02160)发布公告，AnchorMan®左心耳封堵器系统及其导引系统已获得CE标志(表明欧洲经济区内所售产品符合健康、安全及环保标准的认证标志)批准。AnchorMan®左心耳封堵器系统和AnchorMan®左心耳导引系统均已获得中国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1255099.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 心通医疗-B(02160)再涨超5% ANCHORMAN®左心耳封堵器系统及其导引系统获得CE标志批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 心通医疗-B(02160)再涨超5% ANCHORMAN®左心耳封堵器系统及其导引系统获得CE标志批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-27 11:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1255099.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨5.38%，报0.98港元，成交额828.86万港元。消息面上，心通医疗-B(02160)发布公告，AnchorMan®左心耳封堵器系统及其导引系统已获得CE标志(表明欧洲经济区内所售产品符合健康、安全及环保标准的认证标志)批准。AnchorMan®左心耳封堵器系统和AnchorMan®左心耳导引系统均已获得中国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1255099.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02160","symbol_name":"微创心通-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1255099.html","article_id":"2514016810","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514016810","pubTimestamp":1740627868,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，心通医疗-B再涨超5%，截至发稿，涨5.38%，报0.98港元，成交额828.86万港元。消息面上，心通医疗-B发布公告，AnchorMan左心耳封堵器系统及其导引系统已获得CE标志批准。AnchorMan左心耳封堵器系统和AnchorMan左心耳导引系统均已获得中国国家药品监督管理局颁发的批准。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02160":"微创心通-B","BK1583":"高瓴概念","BK4109":"特种化学制品","BK1100":"医疗保健设备","CE":"塞拉尼斯","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"Hong Kong stock Yidong Xintong Medical-B (02160) rose more than 5% ANCHORMAN ® 's left atrial appendage occluder system and its guidance system obtained CE mark approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CE":1,"02160":1},"content_text":"智通财经APP获悉，心通医疗-B(02160)再涨超5%，截至发稿，涨5.38%，报0.98港元，成交额828.86万港元。消息面上，心通医疗-B(02160)发布公告，AnchorMan®左心耳封堵器系统及其导引系统已获得CE标志(表明欧洲经济区内所售产品符合健康、安全及环保标准的认证标志)批准。AnchorMan®左心耳封堵器系统和AnchorMan®左心耳导引系统均已获得中国国家药品监督管理局颁发的批准。AnchorMan®左心耳封堵器系统是目前中国唯一获批的半封闭型左心耳封堵器产品。此外，AnchorMan®左心耳封堵器系统和AnchorMan®左心耳导引系统获得CE标志批准，意味着其创新的研发设计和优异的临床表现达到了国际水平，为其进军欧洲结构性心脏病市场提供了先决条件，亦为其拓展更多国际市场提供了强有力的支撑，是公司发展历程和全球化战略布局中至关重要的里程碑，有望进一步拓宽公司收入来源，提升其全球综合竞争力，并为公司在国际舞台上赢得更多机遇，造福更多结构性心脏病患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514016810","isCrawlerRequest":true}